trial
as of 2026-07-01Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
NCTId NCT05321602
at a glance
Phase 1 · Completed
Enrollment 89 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2022-09-23
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
89 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2021-09-08
Primary completion
2022-09-23
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Neurotransmitter AgentsPsychotic DisordersCentral Nervous System DepressionAntipsychotic AgentsMolecular Mechanisms of Pharmacological ActionSchizophrenia Spectrum and Other Psychotic DisordersSchizophrenia Spectrum and Other Psychotic DisordersPsychotic DisordersSchizophreniaMood DisordersSchizophreniaTranquilizing Agents
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Investigators
1
Rui Li, MDStudy Chair
Sites
9 total
Little Rock, United StatesGarden Grove, United StatesOrange, United StatesTorrance, United StatesMiami Lakes, United StatesAtlanta, United StatesChicago, United StatesGaithersburg, United StatesDeSoto, United States
Facts & assertions
4 sourced
Enrollment
89
Phase
PHASE1
Primary Completion Date
2022-09-23
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication
indication
investigator
person